Table 2.

Baseline characteristics of the patients, their tumors, and long-term survival.

Study	Number	Male	Mean CA19-9	Size	Bismuth–Corlette Type					T1/T2	N0	R0	PN(+)	Median OS	5-OS
					I	II	IIIA	IIIB	IV
Bagante and colleagues16	437	272	102	2.5	67	70	216		84	49	208	296	356	–	–
Morine and colleagues17	22	17	–	–	–	–	–	–		–	15	–	–	–	–
Giuliante and colleagues18	175	100	–	2.7	2	30	133		10	43	105	143	126	–	–
Hakeem and colleagues19	78	45	–	3.0	–	–	–	–	–	36	30	46	69	–	26%
Hu and colleagues20	381	231	348	–	95	92	102		92	–	–	–	–	26	28%
Hoffmann and colleagues21	60	37	251	–	1		15	13	31	30	–	23	–	28	18%
Nakanishi and colleagues22	168	120	199	–	–	–	–	–	25	–	102	152	140	–	–
Li and colleagues23	187	129	–	–	–	–	–	–	–	–	89	141	42	–	30
Yan and colleagues24	131	75	–	–	6	21	45	53	6	–	–	90	–	35	22%
Kimura and colleagues25	183	106	–	–	–	–	–	–	–	107	104	112	–	–	–
Matsuo and colleagues7	157	–	–	3.0	–	–	–	–	–	–	–	120	–	39	32%
Coelen and colleagues26	100	64	143	–	1	6	37	35	21	–	75	72	72	37	–
Sano and colleagues10	99	69	101	–	–	–	–	–	–	40	52	58	32	34	38%
Wang and colleagues27	154	92	–	–	–	–	–	–	–	–	99	138	–	–	–
Titapun and colleagues28	153	113	–	–	5	9	72	63	4	–	103	66	–	20	21%
Unno and colleagues29	125	93	–	–	2	23	33	24	43	40	66	79	–	27	35%
Yubin and colleagues30	115	60	–	–	59	23	10	14	9	–	83	92	–	–	–
Zaydfudim and colleagues31	80	50	–	–	–	–	42	38	–	67	49	74	–	–	–
Bhutiani and colleagues32	256	151	–	3.0	28	36	63	46	48	164	155	–	173	–	–
Cheng and colleagues33	171	113	181	–	–	–	–	–	–	–	69	134	92	–	–
Chen and colleagues34	235	158	–	2.8	17	52	56	110	–	159	172	208	119	–	–
Wang and colleagues35	204	122	–	–	18	40	65	54	27	–	75	153	–	–	24%
Cai and colleagues36	168	96	–	–	18	18	12	30	90	–	108	141	–	–	29%
Kang and colleagues37	403	288	–	–	37	54	132	64	116	124	137	116	–	20	19%
Seyama and colleagues38	58	40	–	–	9	8	14	11	16	2	0	37	49	–	–
DeOliveira and colleagues2	281	163	–	–	–	–	–	–	–	–	202	53	–	13	10%
Silva and colleagues39	45	–	–	–	–	–	–	–	–	–	20	23	–	26	32%
Baton and colleagues12	59	36	–	–	–	–	–	–	–	–	–	46	46	30	22%
Klempnauer and colleagues40	137	83	–	–	8	18	45	58	7	62	96	106	33	21	26%
Nagino and colleagues41	574	381	–	–	88		225		261	–	276	374	387	–
Kosuge and colleagues42	65	50	–	–	4	14	8	31	8	27	58	34	50	28	26%
Neuhaus and colleagues43	95	50	–	–	6	8	27	29	25	–	–	58	–	–	22%
Cheng and colleagues44	75	42	–	–	23	9	37	6	–	–	–	–	21	36	12%
Hasegawa and colleagues45	49	29	–	–	8		3	7	31	–	32	36	28	30	–
Murakami and colleagues46	38	22	–	–	5		33		–	16	23	31	32	22	30%
Lee and colleagues47	302	223	–	–	16	41	131	62	52	187	229	231	218	–	33%
Miyazaki and colleagues48	161	102	–	–	–	–	–	–	–	104	84	102	144	–	30%
Buettner and colleagues49	407	250	–	2.5	56	58	84	95	69	389	269	179	169	24	21%
Chauhan and colleagues50	51	36	–	–	–	–	–	–	–	–	27	37	26	–	–
Chen and colleagues51	138	86	–	–	11	34	43	35	15	83	90	123	–	–	–
Cho and colleagues52	105	67	149	–	12	8	39	18	28	49	59	–	43	36	34%
Dumitrascu and colleagues53	90	52	–	–	22		26	33	9	50	45	68	11	26	27%
Furusawa and colleagues54	144	102	–	–	32		28	23	61	119	76	107	–	–	34%
Saxena and colleagues55	42	23	–	–	3	36	32		1	22	30	27	20	–	24%
Song and colleagues56	230	151	–	–	68		127	125	–	–	–	176	–	39	33%

OS, overall survival; PN, perineural invasion.